<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id><journal-id journal-id-type="publisher-id">BJH</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28369776</article-id><article-id pub-id-type="pmc">6001539</article-id><article-id pub-id-type="doi">10.1111/bjh.14630</article-id><article-id pub-id-type="publisher-id">BJH14630</article-id><article-categories><subj-group subj-group-type="overline"><subject>Correspondence</subject></subj-group><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Clonal haematopoiesis is not prevalent in survivors of childhood cancer</article-title><alt-title alt-title-type="left-running-head">Correspondence</alt-title></title-group><contrib-group><contrib id="bjh14630-cr-0001" contrib-type="author"><name><surname>Collord</surname><given-names>Grace</given-names></name><xref ref-type="aff" rid="bjh14630-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh14630-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh14630-cr-0002" contrib-type="author"><name><surname>Park</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="bjh14630-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh14630-cr-0003" contrib-type="author"><name><surname>Podest&#x000e0;</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="bjh14630-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bjh14630-cr-0004" contrib-type="author"><name><surname>Dagnino</surname><given-names>Monica</given-names></name><xref ref-type="aff" rid="bjh14630-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bjh14630-cr-0005" contrib-type="author"><name><surname>Cilloni</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="bjh14630-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="bjh14630-cr-0006" contrib-type="author"><name><surname>Jones</surname><given-names>David</given-names></name><xref ref-type="aff" rid="bjh14630-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bjh14630-cr-0007" contrib-type="author"><name><surname>Varela</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="bjh14630-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="bjh14630-cr-0008" contrib-type="author"><name><surname>Frassoni</surname><given-names>Francesco</given-names></name><address><email>francesco.l.frassoni@gmail.com</email></address><xref ref-type="aff" rid="bjh14630-aff-0003">
<sup>3</sup>
</xref><xref ref-type="author-notes" rid="bjh14630-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="bjh14630-cr-0009" contrib-type="author"><name><surname>Vassiliou</surname><given-names>George S.</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4337-8022</contrib-id><address><email>gsv20@sanger.ac.uk</email></address><xref ref-type="aff" rid="bjh14630-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh14630-aff-0006">
<sup>6</sup>
</xref><xref ref-type="aff" rid="bjh14630-aff-0007">
<sup>7</sup>
</xref><xref ref-type="author-notes" rid="bjh14630-note-0001">
<sup>&#x02020;</sup>
</xref></contrib></contrib-group><aff id="bjh14630-aff-0001">
<label><sup>1</sup></label>
<institution>Wellcome Trust Sanger Institute</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">UK</country>
</aff><aff id="bjh14630-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Paediatrics</named-content>
<institution>Cambridge University Hospitals NHS Foundation Trust</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">UK</country>
</aff><aff id="bjh14630-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Laboratorio Cellule Staminali e Terapie Cellulari</named-content>
<institution>Istituto Giannina Gaslini IRCCS</institution>
<named-content content-type="city">Genova</named-content>
<country country="IT">Italy</country>
</aff><aff id="bjh14630-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Clinical and Biological Sciences</named-content>
<institution>University of Turin</institution>
<named-content content-type="city">Turin</named-content>
<country country="IT">Italy</country>
</aff><aff id="bjh14630-aff-0005">
<label><sup>5</sup></label>
<institution>Instituto de Biomedicina y Biotecnolog&#x000ed;a de Cantabria</institution>
<named-content content-type="city">Cantabria</named-content>
<country country="ES">Spain</country>
</aff><aff id="bjh14630-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Haematology</named-content>
<institution>University of Cambridge</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">UK</country>
</aff><aff id="bjh14630-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Department of Haematology</named-content>
<institution>Cambridge University Hospitals NHS Foundation Trust</institution>
<named-content content-type="city">Cambridge</named-content>
<country country="GB">UK</country>
</aff><author-notes><fn fn-type="equal" id="bjh14630-note-0001"><label>&#x02020;</label><p>Contributed equally.</p></fn></author-notes><pub-date pub-type="epub"><day>03</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2018</year></pub-date><volume>181</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/bjh.2018.181.issue-4</issue-id><fpage>537</fpage><lpage>539</lpage><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>British Journal of Haematology</italic> published by John Wiley &#x00026; Sons Ltd</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BJH-181-537.pdf"/><kwd-group kwd-group-type="author-generated"><kwd id="bjh14630-kwd-0001">haematopoiesis</kwd><kwd id="bjh14630-kwd-0002">late effects of therapy</kwd><kwd id="bjh14630-kwd-0003">haematopoietic stem cells</kwd><kwd id="bjh14630-kwd-0004">paediatric cancer</kwd><kwd id="bjh14630-kwd-0005">clonal evolution</kwd></kwd-group><counts><fig-count count="0"/><table-count count="1"/><page-count count="3"/><word-count count="1918"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bjh14630</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.1.1 mode:remove_FC converted:14.06.2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Clonal haematopoiesis driven by leukaemia&#x02010;associated somatic mutations is a common feature of ageing (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). This phenomenon, termed clonal haematopoiesis of indeterminate potential (CHIP), is associated with&#x000a0;an increased risk of haematological malignancies and all&#x02010;cause mortality (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). Recent empirical evidence and computational models suggest that mutation acquisition may not be the major rate&#x02010;limiting factor in the emergence of CHIP (Altrock <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0001" ref-type="ref">2015</xref>; McKerrell <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0006" ref-type="ref">2015</xref>; Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>; Young <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0009" ref-type="ref">2016</xref>). Instead, clonal expansion of mutant haematopoietic stem cells (HSCs) probably reflects the interaction between the effects of driver mutations and selection pressures prevailing in the bone marrow microenvironment (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). Notably, cytotoxic therapies have been shown to favour expansion of pre&#x02010;malignant haematopoietic clones (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). Furthermore, both adult and paediatric cancer patients treated with intensive chemoradiotherapy display an earlier onset of ageing&#x02010;associated morbidities and an elevated risk of therapy&#x02010;related myeloid neoplasms (t&#x02010;MN) and other secondary malignancies (Rowland &#x00026; Bellizzi, <xref rid="bjh14630-bib-0007" ref-type="ref">2014</xref>). A recent study in adult cancer patients found that CHIP was more prevalent than in the general population and was strongly associated with t&#x02010;MN and overall mortality (Gibson <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0003" ref-type="ref">2017</xref>). Although CHIP is extremely rare in healthy young individuals, its prevalence and prognostic significance in paediatric cancer patients has not been studied. We therefore performed targeted deep sequencing of peripheral blood DNA from 84 childhood cancer survivors to search for subclonal mutations common in t&#x02010;MN and adult clonal haematopoiesis. No individuals with somatic variants at these loci were identified. Whilst our findings could be explained by a rarity of driver mutations, the fact that human HSCs accrue somatic variants from the first decade of life (Welch <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0008" ref-type="ref">2012</xref>) proposes the alternative possibility that such mutations may not confer clonal advantage in the young.</p><p>We obtained peripheral blood DNA samples from patients enrolled on long&#x02010;term follow&#x02010;up after treatment for a paediatric malignancy and from three age&#x02010;matched controls with no cancer history. Written informed consent was obtained for sample collection and DNA sequencing from all patients or their guardian in accordance with the Declaration of Helsinki and protocols approved by the relevant institutional ethics committees (approval numbers 09REG2015, 1&#x02010;09/12/2015). The median age at cancer diagnosis was 4&#x000b7;5&#x000a0;years, and the commonest malignancies were acute lymphoblastic leukaemia (<italic>n</italic>&#x000a0;=&#x000a0;21), neuroblastoma (<italic>n</italic>&#x000a0;=&#x000a0;17) and non&#x02010;Hodgkin lymphoma (<italic>n</italic>&#x000a0;=&#x000a0;10). Nineteen patients had received a HSC transplant (8 allogeneic and 11 autologous). The median interval between completion of cancer treatment and blood sampling was 6&#x000a0;years (range 2&#x02013;25). Patient characteristics are summarized in Table&#x000a0;<xref rid="bjh14630-sup-0001" ref-type="supplementary-material">SI</xref>.</p><p>We performed targeted next generation sequencing (NGS) using multiplex polymerase chain reaction to amplify 32 regions of 14 genes frequently mutated in CHIP or t&#x02010;MN (Table&#x000a0;<xref rid="bjh14630-tbl-0001" ref-type="table-wrap">1</xref>) (McKerrell <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0006" ref-type="ref">2015</xref>; Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>; Gibson <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0003" ref-type="ref">2017</xref>). For this we extended a previously validated assay that detected clonal haemopoiesis in 2&#x000b7;6% of unselected adults (McKerrell <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0006" ref-type="ref">2015</xref>), to include all coding exons of <italic>TP53</italic> and <italic>PPM1D</italic>, genes implicated in t&#x02010;MN pathogenesis (Rowland &#x00026; Bellizzi, <xref rid="bjh14630-bib-0007" ref-type="ref">2014</xref>; Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>; Gibson <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0003" ref-type="ref">2017</xref>). Primer design and sequencing was performed as described previously (McKerrell <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0006" ref-type="ref">2015</xref>); see Table&#x000a0;<xref rid="bjh14630-sup-0001" ref-type="supplementary-material">SII</xref> for primer sequences. Reads were aligned to human genome build GRCh37 using the Burrows&#x02010;Wheeler Aligner (Li &#x00026; Durbin, <xref rid="bjh14630-bib-0004" ref-type="ref">2010</xref>) and analysed for somatic single nucleotide variants. Allele counts were generated using an in&#x02010;house script (<ext-link ext-link-type="uri" xlink:href="https://github.com/cancerit/alleleCount">https://github.com/cancerit/alleleCount</ext-link>), considering only loci with &#x02265;1000 reads and minimum base and mapping quality of 25 and 35, respectively. Somatic mutations with variant allele frequency (VAF) &#x02265;0&#x000b7;008 (McKerrell <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0006" ref-type="ref">2015</xref>) were sought and examined visually and by interrogation with the Shearwater algorithm (<ext-link ext-link-type="uri" xlink:href="https://github.com/mg14/deepSNV">https://github.com/mg14/deepSNV</ext-link>) (Gerstung <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0002" ref-type="ref">2014</xref>).</p><table-wrap id="bjh14630-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Genomic regions sequenced</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Gene</th><th align="left" valign="top" rowspan="1" colspan="1">Chromosome</th><th align="left" valign="top" rowspan="1" colspan="1">Target codon/exon</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>NRAS</italic>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">p.G12</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>SF3B1</italic>
</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">p.K666; p.K700</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>DNMT3A</italic>
</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">p.R882</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>IDH1</italic>
</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">p.R132</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>KIT</italic>
</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">exon 17</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>NPM1</italic>
</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">exon 12</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>JAK2</italic>
</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">p.V617</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>KRAS</italic>
</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">p.G12</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>IDH2</italic>
</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">p.R140; p.R172</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>PPM1D</italic>
</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">exons 1&#x02013;6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">exons 1&#x02013;12</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>SRSF2</italic>
</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">p.P95</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>ASXL1</italic>
</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">exon 12</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>U2AF1</italic>
</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">p.S34; p.Q157</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The median sequencing depth across regions of interest was 5&#x000b7;3&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup>. No somatic mutations with VAF&#x000a0;&#x02265;&#x000a0;0&#x000b7;008 were observed in any of our patients or controls, demonstrating that CHIP driven by mutations at these loci is not prevalent in young individuals who have received cytotoxic treatment. By contrast, Gibson <italic>et&#x000a0;al</italic> (<xref rid="bjh14630-bib-0003" ref-type="ref">2017</xref>) identified post&#x02010;chemotherapy CHIP (VAF&#x000a0;&#x0003e;&#x000a0;0&#x000b7;02) in 29&#x000b7;9% of 401 adult lymphoma patients. Notably, mutations in <italic>PPM1D</italic>, a regulator of <italic>TP53</italic>, were the commonest CHIP drivers (Gibson <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0003" ref-type="ref">2017</xref>). Similarly, several smaller studies have demonstrated clonal expansion in older patients undergoing chemoradiotherapy for other cancers (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). An investigation of haematopoietic clonal dynamics in 15 adult acute myeloid leukaemia patients found that, after induction chemotherapy, five had marked expansion of clones unrelated to their leukaemia (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). Most clones carried canonical leukaemia mutations and continued to expand years after remission (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). In a study exploring the clonal origins of t&#x02010;MN, <italic>TP53</italic>&#x02010;mutated clones expanded dramatically after cytotoxic treatment, whereas the same mutations demonstrated very modest clonal advantage in healthy individuals (Link &#x00026; Walter, <xref rid="bjh14630-bib-0005" ref-type="ref">2016</xref>). In light of the above, our findings have two plausible explanations: (i) that somatic driver mutations are very uncommon in young individuals even after exposure to chemotherapy or (ii) that accrual of such mutations is insufficient to trigger clonal expansion in this age group. The latter is supported by findings that oncogenic mutations begin accumulating early in life (Welch <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0008" ref-type="ref">2012</xref>) and that cancer&#x02010;associated mutations are less able to drive clonal expansion in young compared to old stem cells (Zhu <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0010" ref-type="ref">2016</xref>). The fact that bona&#x02010;fide driver mutations do not always lead to haematopoietic clonal expansion, even after several years, was highlighted by Young <italic>et&#x000a0;al</italic> (<xref rid="bjh14630-bib-0009" ref-type="ref">2016</xref>), using ultra&#x02010;sensitive sequencing. Therefore our results should not be taken to reflect absence of potentially oncogenic HSC mutations in young cancer survivors. Rather, it is possible that even canonical leukaemogenic mutations may not commonly drive clonal outgrowth in children and young adults despite exposure to extreme haematopoietic stress, implicating age&#x02010;related changes in HSCs and/or their microenvironment as key determinants of relative fitness. More sensitive DNA sequencing methods may enable detection of very rare cells harbouring known CHIP drivers mutations in similar patient cohorts, which would lend support to this hypothesis. Studies of larger numbers of paediatric cancer survivors are needed to identify rare individuals with CHIP after chemoradiotherapy, whose particular characteristics may offer insights into factors facilitating clonal outgrowth of mutated HSCs. Furthermore, in view of the shifting patterns of mutations driving CHIP in different adult age groups (McKerrell <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0006" ref-type="ref">2015</xref>), selective pressures particular to a less mature bone marrow environment may confer clonal advantage on a distinct spectrum of somatic variants in the very young. Although a much broader screening approach is required to identify such mutations, the potential role for CHIP as a biomarker for patient risk&#x02010;stratification (Gibson <italic>et&#x000a0;al</italic>, <xref rid="bjh14630-bib-0003" ref-type="ref">2017</xref>) may render this a worthwhile endeavour.</p><sec id="bjh14630-sec-0003"><title>Author contributions</title><p>GSV, GC and FF conceived and designed the study. NH designed sequencing assays. GC performed experiments and bioinformatics analysis. GC and GSV wrote the manuscript with input from FF. DJ and IV wrote scripts and contributed to analysis strategy. FF, MP, MD and DC contributed to sample acquisition and patient recruitment.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="bjh14630-sup-0001"><caption><p>
<bold>Table&#x000a0;SI.</bold> Patient characteristics</p><p>
<bold>Table&#x000a0;SII.</bold> Primer sequences</p></caption><media xlink:href="BJH-181-537-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="bjh14630-sec-0002"><title>Acknowledgements</title><p>This project was funded by the Wellcome Trust Sanger Institute (grant number WT098051). G.S.V. is funded by a Wellcome Trust Senior Fellowship in Clinical Science (WT095663MA). F.F. is funded by Compagnia di San Paolo Grant: &#x0201c;Le cellule staminali del sangue nei guariti di leucemia&#x0201d; Codice SIME 2013&#x02010;0958 (codice ROL 4201). I.V is funded by the Spanish Ministerio de Econom&#x000ed;a y Competitividad, Programa Ram&#x000f3;n y Cajal.</p></ack><ref-list content-type="cited-references" id="bjh14630-bibl-0001"><title>References</title><ref id="bjh14630-bib-0001"><mixed-citation publication-type="journal" id="bjh14630-cit-0001">
<string-name>
<surname>Altrock</surname>, <given-names>P.M.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>L.L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Michor</surname>, <given-names>F.</given-names>
</string-name> (<year>2015</year>) <article-title>The mathematics of cancer: integrating quantitative models</article-title>. <source xml:lang="en">Nature Reviews Cancer</source>, <volume>15</volume>, <fpage>730</fpage>&#x02013;<lpage>745</lpage>.<pub-id pub-id-type="pmid">26597528</pub-id></mixed-citation></ref><ref id="bjh14630-bib-0002"><mixed-citation publication-type="journal" id="bjh14630-cit-0002">
<string-name>
<surname>Gerstung</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Papaemmanuil</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Campbell</surname>, <given-names>P.J.</given-names>
</string-name> (<year>2014</year>) <article-title>Subclonal variant calling with multiple samples and prior knowledge</article-title>. <source xml:lang="en">Bioinformatics (Oxford, England)</source>, <volume>30</volume>, <fpage>1198</fpage>&#x02013;<lpage>1204</lpage>.</mixed-citation></ref><ref id="bjh14630-bib-0003"><mixed-citation publication-type="journal" id="bjh14630-cit-0003">
<string-name>
<surname>Gibson</surname>, <given-names>C.J.</given-names>
</string-name>, <string-name>
<surname>Lindsley</surname>, <given-names>R.C.</given-names>
</string-name>, <string-name>
<surname>Tchekmedyian</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Mar</surname>, <given-names>B.G.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Jaiswal</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bosworth</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Francisco</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bansal</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Morgan</surname>, <given-names>E.A.</given-names>
</string-name>, <string-name>
<surname>Lacasce</surname>, <given-names>A.S.</given-names>
</string-name>, <string-name>
<surname>Freedman</surname>, <given-names>A.S.</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Jacobsen</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Armand</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Alyea</surname>, <given-names>E.P.</given-names>
</string-name>, <string-name>
<surname>Koreth</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ho</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Soiffer</surname>, <given-names>R.J.</given-names>
</string-name>, <string-name>
<surname>Antin</surname>, <given-names>J.H.</given-names>
</string-name>, <string-name>
<surname>Ritz</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Nikiforow</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Forman</surname>, <given-names>S.J.</given-names>
</string-name>, <string-name>
<surname>Michor</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Neuberg</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Bhatia</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Bhatia</surname>, <given-names>S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ebert</surname>, <given-names>B.L.</given-names>
</string-name> (<year>2017</year>) <article-title>Clonal hematopoiesis associated with adverse outcomes after autologous stem&#x02010;cell transplantation for lymphoma</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, JCO2016716712. [Epub ahead of print]</mixed-citation></ref><ref id="bjh14630-bib-0004"><mixed-citation publication-type="journal" id="bjh14630-cit-0004">
<string-name>
<surname>Li</surname>, <given-names>H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Durbin</surname>, <given-names>R.</given-names>
</string-name> (<year>2010</year>) <article-title>Fast and accurate long&#x02010;read alignment with Burrows&#x02010;Wheeler transform</article-title>. <source xml:lang="en">Bioinformatics (Oxford, England)</source>, <volume>26</volume>, <fpage>589</fpage>&#x02013;<lpage>595</lpage>.</mixed-citation></ref><ref id="bjh14630-bib-0005"><mixed-citation publication-type="journal" id="bjh14630-cit-0005">
<string-name>
<surname>Link</surname>, <given-names>D.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Walter</surname>, <given-names>M.J.</given-names>
</string-name> (<year>2016</year>) <article-title>&#x02018;CHIP'ping away at clonal hematopoiesis</article-title>. <source xml:lang="en">Leukemia</source>, <volume>30</volume>, <fpage>1633</fpage>&#x02013;<lpage>1635</lpage>.<pub-id pub-id-type="pmid">27311932</pub-id></mixed-citation></ref><ref id="bjh14630-bib-0006"><mixed-citation publication-type="journal" id="bjh14630-cit-0006">
<string-name>
<surname>McKerrell</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Park</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Grove</surname>, <given-names>C.S.</given-names>
</string-name>, <string-name>
<surname>Ponstingl</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>, <given-names>J.</given-names>
</string-name>, <collab collab-type="authors">Understanding Society Scientific Group</collab>
, <string-name>
<surname>Crawley</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Craig</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Scott</surname>, <given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Hodkinson</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Baxter</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Rad</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Forsyth</surname>, <given-names>D.R.</given-names>
</string-name>, <string-name>
<surname>Quail</surname>, <given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Zeggini</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Ouwehand</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Varela</surname>, <given-names>I.</given-names>
</string-name> &#x00026; <string-name>
<surname>Vassiliou</surname>, <given-names>G.S.</given-names>
</string-name> (<year>2015</year>) <article-title>Leukemia&#x02010;associated somatic mutations drive distinct patterns of age&#x02010;related clonal hemopoiesis</article-title>. <source xml:lang="en">Cell Reports</source>, <volume>10</volume>, <fpage>1239</fpage>&#x02013;<lpage>1245</lpage>.<pub-id pub-id-type="pmid">25732814</pub-id></mixed-citation></ref><ref id="bjh14630-bib-0007"><mixed-citation publication-type="journal" id="bjh14630-cit-0007">
<string-name>
<surname>Rowland</surname>, <given-names>J.H.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bellizzi</surname>, <given-names>K.M.</given-names>
</string-name> (<year>2014</year>) <article-title>Cancer survivorship issues: life after treatment and implications for an aging population</article-title>. <source xml:lang="en">Journal of Clinical Oncology</source>, <volume>32</volume>, <fpage>2662</fpage>&#x02013;<lpage>2668</lpage>.<pub-id pub-id-type="pmid">25071099</pub-id></mixed-citation></ref><ref id="bjh14630-bib-0008"><mixed-citation publication-type="journal" id="bjh14630-cit-0008">
<string-name>
<surname>Welch</surname>, <given-names>J.S.</given-names>
</string-name>, <string-name>
<surname>Ley</surname>, <given-names>T.J.</given-names>
</string-name>, <string-name>
<surname>Link</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Miller</surname>, <given-names>C.A.</given-names>
</string-name>, <string-name>
<surname>Larson</surname>, <given-names>D.E.</given-names>
</string-name>, <string-name>
<surname>Koboldt</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Wartman</surname>, <given-names>L.D.</given-names>
</string-name>, <string-name>
<surname>Lamprecht</surname>, <given-names>T.L.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Xia</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kandoth</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Fulton</surname>, <given-names>R.S.</given-names>
</string-name>, <string-name>
<surname>McLellan</surname>, <given-names>M.D.</given-names>
</string-name>, <string-name>
<surname>Dooling</surname>, <given-names>D.J.</given-names>
</string-name>, <string-name>
<surname>Wallis</surname>, <given-names>J.W.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Harris</surname>, <given-names>C.C.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>H.K.</given-names>
</string-name>, <string-name>
<surname>Kalicki&#x02010;Veizer</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>O'Laughlin</surname>, <given-names>M.D.</given-names>
</string-name>, <string-name>
<surname>McMichael</surname>, <given-names>J.F.</given-names>
</string-name>, <string-name>
<surname>Delehaunty</surname>, <given-names>K.D.</given-names>
</string-name>, <string-name>
<surname>Fulton</surname>, <given-names>L.A.</given-names>
</string-name>, <string-name>
<surname>Magrini</surname>, <given-names>V.J.</given-names>
</string-name>, <string-name>
<surname>McGrath</surname>, <given-names>S.D.</given-names>
</string-name>, <string-name>
<surname>Demeter</surname>, <given-names>R.T.</given-names>
</string-name>, <string-name>
<surname>Vickery</surname>, <given-names>T.L.</given-names>
</string-name>, <string-name>
<surname>Hundal</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Cook</surname>, <given-names>L.L.</given-names>
</string-name>, <string-name>
<surname>Swift</surname>, <given-names>G.W.</given-names>
</string-name>, <string-name>
<surname>Reed</surname>, <given-names>J.P.</given-names>
</string-name>, <string-name>
<surname>Alldredge</surname>, <given-names>P.A.</given-names>
</string-name>, <string-name>
<surname>Wylie</surname>, <given-names>T.N.</given-names>
</string-name>, <string-name>
<surname>Walker</surname>, <given-names>J.R.</given-names>
</string-name>, <string-name>
<surname>Watson</surname>, <given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Heath</surname>, <given-names>S.E.</given-names>
</string-name>, <string-name>
<surname>Shannon</surname>, <given-names>W.D.</given-names>
</string-name>, <string-name>
<surname>Varghese</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Nagarajan</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Payton</surname>, <given-names>J.E.</given-names>
</string-name>, <string-name>
<surname>Baty</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Kulkarni</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Klco</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Tomasson</surname>, <given-names>M.H.</given-names>
</string-name>, <string-name>
<surname>Westervelt</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Walter</surname>, <given-names>M.J.</given-names>
</string-name>, <string-name>
<surname>Graubert</surname>, <given-names>T.A.</given-names>
</string-name>, <string-name>
<surname>DiPersio</surname>, <given-names>J.F.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Mardis</surname>, <given-names>E.R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wilson</surname>, <given-names>R.K.</given-names>
</string-name> (<year>2012</year>) <article-title>The origin and evolution of mutations in acute myeloid leukemia</article-title>. <source xml:lang="en">Cell</source>, <volume>150</volume>, <fpage>264</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">22817890</pub-id></mixed-citation></ref><ref id="bjh14630-bib-0009"><mixed-citation publication-type="journal" id="bjh14630-cit-0009">
<string-name>
<surname>Young</surname>, <given-names>A.L.</given-names>
</string-name>, <string-name>
<surname>Challen</surname>, <given-names>G.A.</given-names>
</string-name>, <string-name>
<surname>Birmann</surname>, <given-names>B.M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Druley</surname>, <given-names>T.E.</given-names>
</string-name> (<year>2016</year>) <article-title>Clonal haematopoiesis harbouring AML&#x02010;associated mutations is ubiquitous in healthy adults</article-title>. <source xml:lang="en">Nature Communications</source>, <volume>7</volume>, <fpage>12484</fpage>.</mixed-citation></ref><ref id="bjh14630-bib-0010"><mixed-citation publication-type="journal" id="bjh14630-cit-0010">
<string-name>
<surname>Zhu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Finkelstein</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Lopez&#x02010;Terrada</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Utley</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Pounds</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Neale</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Ellison</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Onar&#x02010;Thomas</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Gilbertson</surname>, <given-names>R.J.</given-names>
</string-name> (<year>2016</year>) <article-title>Multi&#x02010;organ mapping of cancer risk</article-title>. <source xml:lang="en">Cell</source>, <volume>166</volume>, <fpage>1132</fpage>&#x02013;<lpage>1146.e7</lpage>.<pub-id pub-id-type="pmid">27565343</pub-id></mixed-citation></ref></ref-list></back></article>